Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Relative Bioavailability of Dabigatran and Diclofenac After Dabigatran Etexilate and Diclofenac Single Dose Alone or Following Concomitant Multiple Oral Administrations in Healthy Male and Female Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02171507
Recruitment Status : Completed
First Posted : June 24, 2014
Last Update Posted : June 24, 2014
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
To investigate the relative bioavailability of dabigatran with and without concomitant administration of diclofenac and the relative bioavailability of diclofenac with and without concomitant administration of dabigatran etexilate

Condition or disease Intervention/treatment Phase
Healthy Drug: Dabigatran etexilate Drug: Diclofenac Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Relative Bioavailability of Dabigatran and Diclofenac After 150 mg b.i.d. Dabigatran Etexilate and Diclofenac at 50 mg Single Dose Alone or Following Concomitant Multiple Oral Administrations in Healthy Male and Female Volunteers (an Open Label, Randomised, Multiple- Dose, Three-way Crossover Study)
Study Start Date : May 2006
Actual Primary Completion Date : July 2006


Arm Intervention/treatment
Active Comparator: Dabigatran etexilate Drug: Dabigatran etexilate
Active Comparator: Diclofenac Drug: Diclofenac
Experimental: Dabigatran etexilate + diclofenac Drug: Dabigatran etexilate
Drug: Diclofenac



Primary Outcome Measures :
  1. AUCτ,ss on Day 4 (area under the concentration-time curve of dabigatran in plasma at steady state over one dosing interval) [ Time Frame: from pre-dose up to 72 hours post-dose ]
  2. Cmax,ss (maximum concentration of dabigatran in plasma at steady state) [ Time Frame: from pre-dose up to 72 hours post-dose ]
  3. Cmax (maximal concentration of diclofenac in plasma) [ Time Frame: from pre-dose up to 72 hours post-dose ]
  4. AUC0-infinity (area under the concentration-time curve of diclofenac in plasma extrapolated to infinity) [ Time Frame: from pre-dose up to 72 hours post-dose ]
  5. aPTT (activated partial thromboplastin time) and ECT (Ecarin clotting time) with and without diclofenac [ Time Frame: from pre-dose up to 72 hours post-dose ]
  6. AUERτ,ss (area under the effect ratio-time curve of dabigatran in plasma at steady state over a uniform dosing interval τ) [ Time Frame: from pre-dose up to 72 hours post-dose ]
  7. ERmax,ss (maximal effect ratio of dabigatran in plasma at steady state) [ Time Frame: from pre-dose up to 72 hours post-dose ]

Secondary Outcome Measures :
  1. AUC0-tz,ss (area under the concentration-time curve of dabigatran in plasma from the time point 0 after the last dose at steady state to the last quantifiable dabigatran plasma concentration within the uniform dosing interval τ) [ Time Frame: from pre-dose up to 72 hours post-dose ]
  2. tz,ss (time of last measurable concentration of dabigatran in plasma within the dosing interval τ at steady state) [ Time Frame: from pre-dose up to 72 hours post-dose ]
  3. tmax,ss (time from last dosing to the maximum concentration of dabigatran in plasma at steady state on Day 4) [ Time Frame: from pre-dose up to 72 hours post-dose ]
  4. CL/Fss (apparent clearance of dabigatran in the plasma at steady state after extravascular multiple dose administration) [ Time Frame: from pre-dose up to 72 hours post-dose ]
  5. CLR,ss (renal clearance of dabigatran at steady state determined over the dosing interval τ) [ Time Frame: from pre-dose up to 72 hours post-dose ]
  6. C min,ss (minimum measured concentration of dabigatran in plasma at steady state over a uniform dosing interval τ) [ Time Frame: from pre-dose up to 72 hours post-dose ]
  7. tmin,ss (time from last dosing to the minimum concentration of dabigatran in plasma at steady state over a uniform dosing interval τ) [ Time Frame: from pre-dose up to 72 hours post-dose ]
  8. Cpre,ss (pre-dose concentration of dabigatran in plasma at steady state immediately before administration of the next dose) [ Time Frame: from pre-dose up to 72 hours post-dose ]
  9. MRTp.o.,ss (mean residence time of dabigatran in the body at steady state after oral administration) [ Time Frame: from pre-dose up to 72 hours post-dose ]
  10. Vz/Fss (apparent volume of distribution during the terminal phase λz at steady state following an extravascular administration) [ Time Frame: from pre-dose up to 72 hours post-dose ]
  11. Aeτ,ss (amount of dabigatran that is eliminated in urine at steady state over a uniform dosing interval τ) [ Time Frame: 0 to 12 h and 12 to 24 h after administration on day 4 ]
  12. feτ,ss (fraction of parent drug eliminated in urine at steady state over a uniform dosing interval τ) [ Time Frame: 0 to 12 h and 12 to 24 h after administration on day 4 ]
  13. AUC0-tz (area under the concentration-time curve of diclofenac and 4´- hydroxydiclofenac in plasma over the time interval 0 to the last quantifiable analyte plasma concentration after single dose administration) [ Time Frame: from pre-dose up to 72 hours post-dose ]
  14. tz (time of last measurable concentration of diclofenac and 4´- hydroxydiclofenac in plasma following a single dose) [ Time Frame: from pre-dose up to 72 hours post-dose ]
  15. %AUCtz-infinity (percentage of the AUC0-infinity that is obtained by extrapolation) for diclofenac and 4´- hydroxydiclofenac [ Time Frame: from pre-dose up to 72 hours post-dose ]
  16. tmax (time from dosing to the maximum concentration of diclofenac and 4´- hydroxydiclofenac in plasma following a single dose) [ Time Frame: from pre-dose up to 72 hours post-dose ]
  17. λz (terminal rate constant in plasma after a single dose) for diclofenac and 4´- hydroxydiclofenac [ Time Frame: from pre-dose up to 72 hours post-dose ]
  18. t1/2 (terminal half-life of diclofenac and 4´- hydroxydiclofenac in plasma after a single dose) [ Time Frame: from pre-dose up to 72 hours post-dose ]
  19. MRTp.o. (mean residence time of diclofenac and 4´- hydroxydiclofenac in the body after single dose oral administration) [ Time Frame: from pre-dose up to 72 hours post-dose ]
  20. CL/F (apparent clearance of diclofenac and 4´- hydroxydiclofenac in the plasma after extravascular single dose administration) [ Time Frame: from pre-dose up to 72 hours post-dose ]
  21. Vz/F (apparent volume of distribution during the terminal phase λz following extravascular dose) for diclofenac and 4´- hydroxydiclofenac [ Time Frame: from pre-dose up to 72 hours post-dose ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion criteria:

  1. Healthy males and females according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (blood pressure, pulse rate), 12-lead electrocardiogram, clinical laboratory tests
  2. Age ≥18 and ≤55 years
  3. Body mass index (BMI) ≥18.5 and BMI ≤29.9 kg/m2
  4. Signed and dated written informed consent prior to admission to the study in accordance with GCP (Good Clinical Practice) and the local legislation

Exclusion criteria:

  1. Clinically relevant gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  2. Relevant surgery of gastrointestinal tract
  3. History of any bleeding disorder including history of gastrointestinal erosions and ulcer or acute blood coagulation defect
  4. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  5. History of relevant orthostatic hypotension, fainting spells or blackouts
  6. Chronic or relevant acute infections
  7. History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the objectives of the trial as judged by the investigator
  8. Intake of drugs with a long half-life (>24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
  9. Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial
  10. Participation in another trial with an investigational drug within two months prior to administration or during the trial
  11. Alcohol abuse (more than 60 g/day)
  12. Drug abuse
  13. Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
  14. Excessive physical activities (within one week prior to administration or during the trial)
  15. Any laboratory value outside the reference range that is of clinical relevance
  16. Subjects with abnormal thrombocyte counts and any relevant deviation in the assessment of platelet function (PFA test) must be excluded
  17. Inability to comply with dietary regimen of study centre
  18. Females of child bearing potential who are pregnant, breast feeding or who are either not surgically sterile or are sexually active and not using an acceptable form of contraception as either the oral contraceptives since at least two months and the double barrier method, i.e. intrauterine device with spermicide and condom for the male partner
  19. Male subjects must agree to minimize the risk of female partners becoming pregnant from the first dosing day until 3 months after the completion of the post study medical examination. Acceptable methods of contraception comprises barrier contraception and a medically accepted contraceptive method for the female partner (intra-uterine device with spermicide, hormonal contraceptive since at least two month)
  20. Planned surgeries within four weeks following the end-of study examination
  21. Intake of medication, which influences the blood clotting, i.e., acetylsalicylic acid, cumarin etc.
  22. The subject is able to understand and comply with protocol requirements, instructions and protocol-stated restrictions
  23. Vulnerable subjects (e.g. persons kept in detention).

Layout table for additonal information
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT02171507     History of Changes
Other Study ID Numbers: 1160.7
First Posted: June 24, 2014    Key Record Dates
Last Update Posted: June 24, 2014
Last Verified: June 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Diclofenac
Dabigatran
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antithrombins
Serine Proteinase Inhibitors
Protease Inhibitors
Anticoagulants